Volume 38, Issue 3

Search all Cardiovascular Drugs and Therapy articles

June 2024

31 articles in this issue

Instent CTO—What Is the Best Treatment Strategy?
Mark Sahyouni
George A. Stouffer
Editorial 25 January 2024 Pages: 393 - 394
Poking and Prodding So They Take Their Pills
Revati Reddy
James C. Blankenship
Editorial 11 July 2023 Pages: 395 - 396
When Less is More: Drug-Coated Balloons Threaten a Paradigm Revolution
Bilal Alqam
James C Blankenship
Editorial 19 December 2023 Pages: 397 - 399
Open Issues in the Management of Otcagerian Patients with Atrial Fibrillation and Chronic Kidney Disease: Are we Ready for Left Atrial Appendage Occlusion (LAAO) as First-Line Therapy for Thromboembolic Risk Prevention?
Francesco Condello
Angelica Cersosimo
Paolo Pagnotta
Editorial 26 January 2024 Pages: 401 - 403
Impairment of Vascular Homeostasis in Acute Heart Failure: Enter the Monocyte?
Saifei Liu
Indy AJ Lawrie
John D. Horowitz
Invited Editorial 23 March 2024 Pages: 405 - 409
Beyond Hepatoprotection—The Cardioprotective Effects of Bicyclol in Diabetes
Arun Samidurai
Rakesh C. Kukreja
Invited Editorial 06 December 2023 Pages: 411 - 413
C/EBP Homologous Protein: A Potential Therapeutic Target for Atherosclerosis Treatment?
Jinjiao Shan
Sanlong Liu
Jingguang Zhu
Letter to the Editor 16 January 2023 Pages: 415 - 415
Possible Cardioprotective Effects of Lactate Infusion After Cardiac Arrest or Prolonged Myocardial Ischemia
Takashi Koyama
Letter to the Editor 14 November 2023 Pages: 417 - 418
IL-33 in Atherosclerosis: An Insufficiently Explored and Controversial Research Area
Yanyan Ye
Fangyuan Chang
Yingchun Xu
Letter to the Editor 31 January 2024 Pages: 419 - 420
The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence
Chia Siang Kow
Dinesh Sangarran Ramachandram
Syed Shahzad Hasan
Letter to the Editor 08 July 2023 Pages: 421 - 422
MicroRNA-92a in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area
Jin-Zhen Cui
Yue-Min Yuan
Yan-Yu Lin
Letter to the Editor 01 December 2023 Pages: 423 - 424
Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin
Tugba Ertan-Bolelli
Kayhan Bolelli
F. Burcu Belen-Apak
Original Article 19 November 2022 Pages: 425 - 432
Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial
Kishal Lukhna
Helison R. P. do Carmo
Derek M. Yellon
Original Article Open access 29 November 2022 Pages: 433 - 445
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study
Roy O. Mathew
Mandeep S. Sidhu
Michael E. Farkouh
Original Article 29 November 2022 Pages: 447 - 457
Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials
Qingtao Hou
Yuqin Chen
Caishuang Pang
Original Article 30 November 2022 Pages: 459 - 469
Left Bundle Branch Area Pacing versus Biventricular Pacing for Cardiac Resynchronization Therapy on Morbidity and Mortality
Yixiu Liang
Zilong Xiao
Junbo Ge
Original Article 02 December 2022 Pages: 471 - 481
Left Ventricular Thrombus Management After Acute Myocardial Infarction in Clinical Practice: Results from LEVITATION Survey and Narrative Review
Luca A. F. Di Odoardo
Matteo Bianco
Enrico Cerrato
Original Article 20 December 2022 Pages: 483 - 492
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
Wolfgang Koenig
Lorena Garcia Conde
Frederick J. Raal
Original Article Open access 23 December 2022 Pages: 493 - 503
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Wei-Chieh Lee
Ting-Wei Liao
Mien-Cheng Chen
Original Article Open access 07 January 2023 Pages: 505 - 515
The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients
Weiguo Fan
Hualong Liu
Kui Hong
Original Article 10 January 2023 Pages: 517 - 525
Mitogen-Activated Protein Kinases Mediate Adventitial Fibroblast Activation and Neointima Formation via GATA4/Cyclin D1 Axis
Jing Chen
Jin-Qiu Wei
Xiao-Dong Li
Original Article 18 January 2023 Pages: 527 - 538
Vaccine Targeting Alpha 1D-Adrenergic Receptor Improved Metabolic Syndrome in Mice
Xin Li
Wenrui Ma
Zihua Zhou
Original Article Open access 19 January 2023 Pages: 539 - 554
Bicyclol Alleviates Streptozotocin-induced Diabetic Cardiomyopathy By Inhibiting Chronic Inflammation And Oxidative Stress
Lingxi Zhang
Chenghong Hu
Ying He
Original Article 20 January 2023 Pages: 555 - 568
IL-33 Suppresses the Progression of Atherosclerosis via the ERK1/2-IRF1-VCAM-1 Pathway
Zhang Qian
Feng Shaofang
Liu Chao
Original Article 14 November 2023 Pages: 569 - 580
PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
Umut Kocabaş
Isil Ergin
on behalf of the ANATOLIA-AF . study investigators
Original Article 17 December 2022 Pages: 581 - 599
Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study
Umut Kocabaş
Isil Ergin
on behalf of the ANATOLIA-A. F. study investigators
Correction 19 January 2023 Pages: 601 - 603
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Jeffrey Triska
Faris Haddadin
Hani Jneid
Review Article 13 July 2022 Pages: 605 - 619
Influence of Genetic and Epigenetic Factors of P2Y₁₂ Receptor on the Safety and Efficacy of Antiplatelet Drugs
Dorota Danielak
Kornel Pawlak
Marta Karaźniewicz-Łada
Review Article Open access 09 August 2022 Pages: 621 - 636
Direct Oral Anticoagulants: Navigating Through Clinical Challenges
Maria Ioannou
Elena Leonidou
Angeliki Mouzarou
Review Article 08 August 2023 Pages: 637 - 650
Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension
Justin K. Lui
Ruchika A. Sangani
Elizabeth S. Klings
Short Communication 06 January 2023 Pages: 651 - 656
Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis‑Related Pulmonary Hypertension
Justin K. Lui
Ruchika A. Sangani
Elizabeth S. Klings
Correction 20 January 2023 Pages: 657 - 657

Volume 38, Issue 3

Instent CTO—What Is the Best Treatment Strategy?

Poking and Prodding So They Take Their Pills

When Less is More: Drug-Coated Balloons Threaten a Paradigm Revolution

Open Issues in the Management of Otcagerian Patients with Atrial Fibrillation and Chronic Kidney Disease: Are we Ready for Left Atrial Appendage Occlusion (LAAO) as First-Line Therapy for Thromboembolic Risk Prevention?

Impairment of Vascular Homeostasis in Acute Heart Failure: Enter the Monocyte?

Beyond Hepatoprotection—The Cardioprotective Effects of Bicyclol in Diabetes

C/EBP Homologous Protein: A Potential Therapeutic Target for Atherosclerosis Treatment?

Possible Cardioprotective Effects of Lactate Infusion After Cardiac Arrest or Prolonged Myocardial Ischemia

IL-33 in Atherosclerosis: An Insufficiently Explored and Controversial Research Area

The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence

MicroRNA-92a in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area

Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin

Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial

Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study

Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials

Left Bundle Branch Area Pacing versus Biventricular Pacing for Cardiac Resynchronization Therapy on Morbidity and Mortality

Left Ventricular Thrombus Management After Acute Myocardial Infarction in Clinical Practice: Results from LEVITATION Survey and Narrative Review

Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease

The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients

Mitogen-Activated Protein Kinases Mediate Adventitial Fibroblast Activation and Neointima Formation via GATA4/Cyclin D1 Axis

Vaccine Targeting Alpha 1D-Adrenergic Receptor Improved Metabolic Syndrome in Mice

Bicyclol Alleviates Streptozotocin-induced Diabetic Cardiomyopathy By Inhibiting Chronic Inflammation And Oxidative Stress

IL-33 Suppresses the Progression of Atherosclerosis via the ERK1/2-IRF1-VCAM-1 Pathway

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study

Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study

The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Influence of Genetic and Epigenetic Factors of P2Y₁₂ Receptor on the Safety and Efficacy of Antiplatelet Drugs

Direct Oral Anticoagulants: Navigating Through Clinical Challenges

Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension

Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis‑Related Pulmonary Hypertension

Navigation